We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
"SHALL" WE DANCE? INTERPRETING THE BPCIA'S PATENT PROVISIONS.
- Authors
Tanaka, Jon
- Abstract
The article focuses on the decision of the U.S. Court of Appeals for the Federal Circuit in the case Amgen Inc. v. Sandoz Inc. on patent dance described in the Biologics Price Competition and Innovation Act (BPCIA) for biosimilar drug approval was not mandatory. It mentions that the U.S. Congress intended the patent dance to be mandatory to maintain an efficient and effective patent dispute resolution process for biosimilar and original biologic drug makers.
- Subjects
AMGEN Inc.; SANDOZ Inc.; BIOLOGICALS -- Law &; legislation; DRUG approval laws; DISPUTE resolution; ACTIONS &; defenses (Law)
- Publication
Berkeley Technology Law Journal, 2016, Vol 31, p659
- ISSN
1086-3818
- Publication type
Article
- DOI
10.15779/Z383S0S